Expression of c-kit in Common Benign and Malignant Breast Lesions

Kondi-Pafiti, A; Arkadopoulos, Nikolaos; Gennatas, Constantine; Michalaki, Vasiliki; Frangou-Plegmenou, Matrona; Chatzipantelis, Paschalis

doi:10.1177/548.6519

Cited by 28 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were also reported by Kondi-Pafiti et al (2010) and Amin et al (2012). Similar results were also reported by Kondi-Pafiti et al (2010) and Amin et al (2012).…”

Section: Discussionsupporting

confidence: 92%

Expression of CD117 in normal and neoplastic breast tissue

Elsayed¹,

Shafeek²

2013

Egyptian Journal of Pathology

View full text Add to dashboard Cite

“…Similar results were also reported by Kondi-Pafiti et al (2010) and Amin et al (2012). Similar results were also reported by Kondi-Pafiti et al (2010) and Amin et al (2012).…”

Section: Discussionsupporting

confidence: 92%

Expression of CD117 in normal and neoplastic breast tissue

Elsayed¹,

Shafeek²

2013

Egyptian Journal of Pathology

View full text Add to dashboard Cite

“…21,22 As for scoring criteria, we used a 1% cutoff in view of the fact that CD117 is not normally expressed in breast stromal cells. 23 Hence, even a low percentage of protein expression could indicate an abnormal state. This is exemplified by our study in which cases that were CD117 positive on immunohistochemistry demonstrated a low percentage of positive cells.…”

Section: Discussionmentioning

confidence: 99%

CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival

et al. 2015

View full text Add to dashboard Cite

and 5 Duke-NUS Graduate Medical School, Singapore CD117 (c-kit) is a type III receptor tyrosine kinase encoded by the KIT gene. Deregulation of expression and mutations in the gene are implicated in various tumors. Reports of CD117 expression in phyllodes tumors have been controversial. We aim to investigate the protein expression of CD117 and mutations in the KIT gene in phyllodes tumors, and correlate the findings with pathological parameters and clinical outcome. A total of 272 cases were included in this study. CD117 expression was investigated by immunohistochemistry on tissue microarray sections. Toluidine blue staining was performed to indicate mast cells. Overall, 28 (10%) cases were CD117 positive. CD117 expression was significantly associated with tumor grade (Po0.001), increased stromal hypercellularity (P ¼ 0.003), stromal atypia (P ¼ 0.01), and stromal mitotic activity (Po0.001), permeative microscopic margins (P ¼ 0.002), and presence of hemorrhage (P ¼ 0.001). Expression was also associated with poorer overall survival (P ¼ 0.003). Nineteen cases were further selected for mutation screening through the Affymetrix OncoScan platform. No mutation of the KIT gene was found. Despite a lack of mutations in the KIT gene, CD117 protein expression is associated with unfavorable pathological parameters and poorer prognosis, suggesting an underlying role in the biology of phyllodes tumors.

show abstract

“…Several studies have identified c-Kit-expressing interstitial cells in the stromal compartment of human prostate [77–79]. Altered patterns of c-Kit expression have been reported in benign lesions of prostate and breast tissues [80, 81]. It has been shown that the c-Kit expression and number of c-Kit(+) interstitial cells were significantly higher in BPH than those of the normal prostate.…”

Section: Stem Cell In Benign Prostate Hyperplasia (Bph)mentioning

confidence: 99%

Prostate Stem Cells in the Development of Benign Prostate Hyperplasia and Prostate Cancer: Emerging Role and Concepts

Prajapati

Gupta

Mistry

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Benign Prostate hyperplasia (BPH) and prostate cancer (PCa) are the most common prostatic disorders affecting elderly men. Multiple factors including hormonal imbalance, disruption of cell proliferation, apoptosis, chronic inflammation, and aging are thought to be responsible for the pathophysiology of these diseases. Both BPH and PCa are considered to be arisen from aberrant proliferation of prostate stem cells. Recent studies on BPH and PCa have provided significant evidence for the origin of these diseases from stem cells that share characteristics with normal prostate stem cells. Aberrant changes in prostate stem cell regulatory factors may contribute to the development of BPH or PCa. Understanding these regulatory factors may provide insight into the mechanisms that convert quiescent adult prostate cells into proliferating compartments and lead to BPH or carcinoma. Ultimately, the knowledge of the unique prostate stem or stem-like cells in the pathogenesis and development of hyperplasia will facilitate the development of new therapeutic targets for BPH and PCa. In this review, we address recent progress towards understanding the putative role and complexities of stem cells in the development of BPH and PCa.

show abstract

Expression of c-kit in Common Benign and Malignant Breast Lesions

Cited by 28 publications

References 29 publications

Expression of CD117 in normal and neoplastic breast tissue

Expression of CD117 in normal and neoplastic breast tissue

CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival

Prostate Stem Cells in the Development of Benign Prostate Hyperplasia and Prostate Cancer: Emerging Role and Concepts

Contact Info

Product

Resources

About